Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Aug 1;38(10):1513-1522.
doi: 10.1097/QAD.0000000000003947. Epub 2024 Jun 25.

MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIV

Leanne McCabe  1 , James E Burns  2   3 , Arash Latifoltojar  4 , Frank A Post  5   6 , Julie Fox  6   7 , Erica Pool  2   3 , Anele Waters  7 , Beatriz Santana  5 , Lucy Garvey  8 , Margaret Johnson  9 , Ian McGuinness  8 , Manil Chouhan  4 , Jonathan Edwards  9 , Anna L Goodman  1   7 , Graham Cooke  8   10 , Claire Murphy  1 , Yolanda Collaco-Moraes  1 , Helen Webb  1 , Adam Gregory  1 , Fatima Mohamed  1 , Mary Rauchenberger  1 , Stephen D Ryder  11 , Chris Sandford  3 , Jason V Baker  12 , Brian Angus  10 , Christoph Boesecke  13 , Chloe Orkin  14   15 , Shonit Punwani  4 , Andrew Clark  16 , Richard Gilson  2   3 , David Dunn  1 , Sarah L Pett  1   2   3 ; the MAVMET Study group
Affiliations
Randomized Controlled Trial

MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIV

Leanne McCabe et al. AIDS. .

Abstract

Objective: Metabolic dysfunction associated fatty liver disease (MAFLD) is over-represented in people with HIV (PWH). Maraviroc (MVC) and/or metformin (MET) may reduce MAFLD by influencing inflammatory pathways and fatty acid metabolism.

Design: Open-label, 48-week randomized trial with a 2 x 2 factorial design.

Setting: Multicenter HIV clinics.

Participants: Nondiabetic, virologically suppressed PLWH, aged at least 35 years, with confirmed/suspected MAFLD (≥1 biochemical/anthropometric/radiological/histological features).

Intervention: Adjunctive MVC; MET; MVC+MET vs. antiretroviral therapy (ART) alone.

Primary outcome: Change in liver fat fraction (LFF) between baseline and week-48 using magnetic resonance proton density fat fraction (MR PDFF).

Results: Six sites enrolled 90 participants (93% male; 81% white; median age 52 [interquartile range, IQR 47-57] years) between March 19, 2018, and November 11, 2019. Seventy percent had imaging/biopsy and at least one 1 MAFLD criteria. The analysis included 82/90 with week-0 and week-48 scans. Median baseline MR PDFF was 8.9 (4.6-17.1); 40, 38, 8, and 14% had grade zero, one, two, and three steatosis, respectively. Mean LFF increased slightly between baseline and follow-up scans: 2.22% MVC, 1.26% MET, 0.81% MVC+MET, and 1.39% ART alone. Prolonged intervention exposure (delayed week-48 scans) exhibited greater increases in MR PDFF (estimated difference 4.23% [95% confidence interval, 95% CI 2.97-5.48], P < 0.001). There were no differences in predicted change for any intervention compared to ART alone: MVC (-0.42% [95% CI -1.53 to 0.68, P = 0.45]), MET (-0.62 [-1.81 to 0.56, P = 0.30]), and MVC+MET (-1.04 [-2.74 to 0.65, P = 0.23]). Steatosis grade remained unchanged in 55% and increased in 24%.

Conclusion: Baseline levels of liver fat were lower than predicted. Contrary to our hypothesis, neither MVC, MET, or the combination significantly reduced liver fat as measured by MRPDFF compared to ART alone.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Fig. 1
Fig. 1
CONSORT statement.
Fig. 2
Fig. 2
Scatter plot of W0 liver fat versus W48 liver fat measured using magnetic resonance proton density fat fraction.
See this image and copyright information in PMC

References

    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64:73–84. - PubMed
    1. Maurice JB, Patel A, Scott AJ, Patel K, Thursz M, Lemoine M. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. AIDS 2017; 31:1621–1632. - PubMed
    1. Lemoine M, Assoumou L, Girard PM, Valantin MA, Katlama C, De Wit S, et al. . ANRS-ECHAM group. Screening HIV patients at risk for NAFLD using MRI-PDFF and transient elastography: a European multicenter prospective study. Clin Gastroenterol Hepatol 2023; 21:713–722.e3. - PubMed
    1. Hoyumpa AM, Jr, Greene HL, Dunn GD, Schenker S. Fatty liver: biochemical and clinical considerations. Am J Dig Dis 1975; 20:1142–1170. - PubMed
    1. Thomsen C, Becker U, Winkler K, Christoffersen P, Jensen M, Henriksen O. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reason Imaging 1994; 12:487–495. - PubMed

Publication types